Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

sacituzumab

sacituzumab is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — sacituzumab
Class
—
Route
—
Patents
0
Programs
12
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

sacituzumab is an FDA-listed pharmaceutical active ingredient.

Key facts

INN sacituzumab

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Sacituzumab Govitecan-hziy Phase 3 · Gilead Sciences Ireland · Triple Negative Breast Cancer
  2. Sacituzumab tirumotecan Phase 3 · Merck KGaA, Darmstadt · Breast Neoplasms
  3. Sacituzumab tirumotecan Phase 3 · Merck KGaA, Darmstadt · Non Small Cell Lung Cancer
  4. Sacituzumab tirumotecan Phase 3 · Merck KGaA, Darmstadt · Non-small Cell Lung Cancer (NSCLC)
  5. CO40115 Phase 2 · HOFFMANN-LA ROCHE · Metastatic breast cancer, including triple negative breast c
  6. MK-2870-027 Phase 2 · MSD Merck Sharp · Intermediate-risk Non-muscle Invasive Bladder Cancer
  7. Sacituzumab Tirumotecan Phase 2 · Chinese Academy of · Extensive-Stage Small Cell Lung Cancer
  8. Sacituzumab Tirumotecan and Limertinib Phase 2 · Chinese Academy of · EGFR-mutant Non-small Cell Lung Cancer

Frequently asked questions

What is sacituzumab?

sacituzumab is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.